Novo Nordisk initiated study validates the power of proteomics to provide unique insights into mechanisms of action and expanded drug indications as well as the potential for shorter and smaller clinical trials SOUTH SAN FRANCISCO, Calif. , Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif. , Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm , PhD, will present at the upcoming 43 rd Annual J.P. Morgan Healthcare Conference taking place on January 13 th - 16 th at
The KREX ™ offering provides additional high plex proteomic solutions for biopharma and translational research end markets SOUTH SAN FRANCISCO, Calif. November 21, 2024 -- Standard BioTools Inc. (Nasdaq: LAB) ("Standard BioTools" or the "Company") today announced the addition of KREX™ precision
SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024 . Kim, a co-founder and most recently Chief Operating
SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that its management team will participate in the following investor conferences in the month of November: UBS Global Healthcare Conference on November 12 th , 2024 President and CEO,
SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) today announced unaudited interim financial results for the third quarter ended September 30, 2024 . Recent Highlights: Reported third quarter 2024 revenue of $45 million Ongoing
SOUTH SAN FRANCISCO, Calif. , Oct. 16, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024 , after the close of the market. The Company’s management will host a conference call and
Cerebrospinal fluid, cell lysates and tissue homogenates open new avenues for biomarker discovery in oncology and neurology SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced that the SomaScan ® 11K Platform now includes protein
Researchers used Standard BioTools’ high-content SomaScan® Platform and SomaSignal™ tests for MASH/NASH to identify 69 blood biomarkers that correlate with clinical measures of liver disease SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced its President and Chief Executive Officer, Michael Egholm , PhD, will present at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference taking place Wednesday September
